

ERITREA INACTIVATED POLIO VACCINE (IPV) SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Eritrea

2. Grant Number: 1518-ERI-25b-X / 15-ERI-08h-Y

3. Date of Decision Letter: 31 March 2015

4. Date of the Partnership Framework Agreement: 16 April 2013

5. Programme Title: NVS, IPV Routine

6. Vaccine type: Inactivated Polio Vaccine (IPV)

 Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. Programme Duration²: 2015 - 2018

Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):

Please note that endorsed or approved amount for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.

	2015	2016	2017	Total ³
Programme Budget (US\$)	US\$157,500	US\$302,500	US\$238,000	US\$698,000

10. Vaccine Introduction Grant: US\$ 100,000

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴

Type of supplies to be purchased	2015	2016
with Gavi funds in each year		
Number of IPV vaccines doses	76,600	147,200
Number of AD syringes	74,000	140,100
Number of safety boxes	825	1,550
Annual Amounts (US\$)	US\$157,500	US\$302,500

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This is the amount that Gavi has approved.



14. Co-financing obligations: Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, Eritrea is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: Not applicable

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

Reports, documents and other deliverables	Due dates	
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat	

17. Financial Clarifications: Not applicable.

*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements

18. Other conditions:

If Eritrea envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Eritrea.

REMINDER: As a Partnership Framework Agreement requirement: "...the government shall maintain, where available at a reasonable cost, all risk property insurance on the Programme assets (including vaccines and vaccine related supplies) and comprehensive general liability insurance with financially sound and reputable insurance companies". In this context, kindly provide Gavi with a copy of such insurance policy to ensure compliance with this requirement.

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

blade to hi

31 March 2015